Interpretation and Management of Elevated Alpha-Fetoprotein (AFP) Levels

Maternal Serum AFP (MSAFP) in Pregnancy

The American College of Medical Genetics recommends screening between 16-18 weeks of gestation for optimal detection of neural tube defects and other fetal abnormalities 1, 2.
Obtain informed consent before testing, as some patients may decline screening for religious or ethical reasons 1, 2.
For minimally elevated values, obtain a second serum specimen if time permits and the elevation is minimal 1, 2.
Proceed directly to ultrasound without a second sample if the result is very elevated or pregnancy is advanced 1, 2.
Perform level I ultrasound to exclude incorrect gestational age, multiple gestation, and fetal demise 1, 2.
If these are excluded, refer promptly to a center with level II ultrasound and amniocentesis capabilities 1, 2.
Proceed with amniocentesis for AFP and acetylcholinesterase (AChE) testing 2, 3, 4.
Pregnant women with insulin-dependent diabetes mellitus (IDDM) have lower AFP levels on average, requiring separate reference ranges for interpretation 1, 2.
Report results as multiples of the median (MoM) with individualized risk assessment based on patient characteristics 1, 2.

AFP is the main circulating protein in fetal blood and declines rapidly after birth, making elevation under 1 month of age physiological 5.
Obtain serial AFP measurements every 2-4 weeks to distinguish physiological descending values from pathological persistent or ascending elevations 5.
If AFP values do not consistently decrease or increase, immediate investigation is required 5.
Complete liver function tests: AST, ALT, direct and indirect bilirubin, alkaline phosphatase, GGT 5.
Synthetic liver function: PT, PTT, albumin 5.
Succinylacetone in blood and urine to screen for tyrosinemia type 1 5.
Complete abdominal ultrasound to evaluate hepatomegaly, liver masses, and anatomy 5.
If ultrasound shows abnormalities or AFP continues rising, proceed to MRI with hepatobiliary contrast 5.
For tyrosinemia type 1 (elevated succinylacetone), start NTBC therapy immediately 5.
Restrict dietary phenylalanine and tyrosine 5.
Monitor AFP continuously—it should decrease during the first year of treatment 5.
If AFP does not decrease or increases, perform imaging immediately to rule out hepatocellular carcinoma 5.
Normal AFP does not exclude malignancy—continuous surveillance with periodic imaging is crucial even with normal AFP values 5, 6.

Validate with repeat testing if significantly elevated 6.
Measure tumor markers: CA19-9 (elevated in 69% of cholangiocarcinoma) and CEA 7.
Complete liver function tests and synthetic function markers 5.
Contrast-enhanced MRI with MRCP is superior to CT for bile duct anatomy, masses, and lesion characterization due to lack of radiation and better tissue characterization 6, 7.
Ultrasound is appropriate for initial evaluation of hepatic masses 6.
For patients with choledochal cysts, type I and IV cysts carry approximately 5% lifetime malignancy risk, increasing substantially with age 7.
65% of cholangiocarcinoma patients are over 65 years old, making age a significant independent risk factor 7.
Lifelong surveillance is required even after complete excision, with imaging and tumor markers at 6-month intervals 7.
For patients with hemangioma and elevated AFP, repeat AFP in 6 weeks for moderate elevations 6.
If two successive increases occur, proceed to MRI 6.
Interpret AFP using age-appropriate reference ranges 6.

Conditions associated with very elevated amniotic fluid AFP and positive AChE: open neural tube defects, gastroschisis, congenital nephrosis, and cystic hygroma fluid aspiration 3, 4.
Omphalocele shows normal to elevated AFP with AChE negative in >95% of cases 3, 4.
Positive results (elevated AFP and/or positive AChE) should be transmitted within one working day by phone and/or fax 3, 4.
Report results in both mass units and interpretive units (MoM) 3, 4.
Do not report elevated amniotic fluid AFP until all reflexive testing is complete 3, 4.